De FUTURE trial; een multicenter RCT naar MRI-geleide prostaatbiopten: Vergelijking van drie technieken van target biopten en vergelijking met systematische biopten

O. Wegelin; L. Exterkate; J. O. Barentsz; M. G. van der Leest; J. C. Kelder; J. A. Kummer; W. Vreuls; P. C. de Bruin; T. F. de Vocht; J. E. Nuininga; J. L.H.R. Bosch; D. M. Somford; H. H.E. van Melick

doi:10.1007/s13629-019-0252-9

De FUTURE trial; een multicenter RCT naar MRI-geleide prostaatbiopten: Vergelijking van drie technieken van target biopten en vergelijking met systematische biopten

Translated title of the contribution: The FUTURE trial: a multicenter RCT on MRI-guided prostate biopsies: Comparison of three techniques of targeted biopsies and comparison with systematic biopsies

O. Wegelin, L. Exterkate^*, J. O. Barentsz, M. G. van der Leest, J. C. Kelder, J. A. Kummer, W. Vreuls, P. C. de Bruin, T. F. de Vocht, J. E. Nuininga, J. L.H.R. Bosch, D. M. Somford, H. H.E. van Melick

^*Corresponding author for this work

Department of Urological Oncology

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

The FUTURE trial is a multicenter RCT on 3 MRI-based target biopsy (TB) techniques among patients with negative systematic biopsies (SBs) and persisting suspicion of prostate cancer. Between 2014 and 2017 665 patients underwent multiparametric MRI. 234 (35%) patients with a PIRADS ≥3 lesion were randomised 1:1:1 for TB: in-bore MRI (MRI-TB), MRI/ultrasound fusion (FUS-TB), and cognitive fusion (COG-TB). After FUS-TB and COG-TB additional SB was performed. No significant differences in prostate cancer detection and significant prostate cancer were found (MRI-TB 54.5%/32.5%, FUS-TB 49.4%/34.2%, and COG-TB 43.6%/33.3%, p = 0.39/p = 0.98). Combined SBs and TBs versus TBs alone resulted in 1% more csPCa detection (35% vs 34%). There was no significant advantage of one TB technique for the detection of overall prostate cancer, nor for clinically significant prostate cancer. The additional value of SBs was limited.

Translated title of the contribution	The FUTURE trial: a multicenter RCT on MRI-guided prostate biopsies: Comparison of three techniques of targeted biopsies and comparison with systematic biopsies
Original language	Dutch
Pages (from-to)	146-156
Number of pages	11
Journal	Tijdschrift voor Urologie
Volume	9
Issue number	8
DOIs	https://doi.org/10.1007/s13629-019-0252-9
Publication status	Published - 1 Dec 2019

Keywords

biopsy
diagnosis
MRI
prostate cancer

Access to Document

10.1007/s13629-019-0252-9

Wegelin2019_Article_DeFUTURETrialEenMulticenterRCTFinal published version, 1.14 MB

Cite this

Wegelin, O., Exterkate, L., Barentsz, J. O., van der Leest, M. G., Kelder, J. C., Kummer, J. A., Vreuls, W., de Bruin, P. C., de Vocht, T. F., Nuininga, J. E., Bosch, J. L. H. R., Somford, D. M., & van Melick, H. H. E. (2019). De FUTURE trial; een multicenter RCT naar MRI-geleide prostaatbiopten: Vergelijking van drie technieken van target biopten en vergelijking met systematische biopten. Tijdschrift voor Urologie, 9(8), 146-156. https://doi.org/10.1007/s13629-019-0252-9

@article{4fc93b8f857144fa9313065411df5cd6,

title = "De FUTURE trial; een multicenter RCT naar MRI-geleide prostaatbiopten: Vergelijking van drie technieken van target biopten en vergelijking met systematische biopten",

abstract = "The FUTURE trial is a multicenter RCT on 3 MRI-based target biopsy (TB) techniques among patients with negative systematic biopsies (SBs) and persisting suspicion of prostate cancer. Between 2014 and 2017 665 patients underwent multiparametric MRI. 234 (35%) patients with a PIRADS ≥3 lesion were randomised 1:1:1 for TB: in-bore MRI (MRI-TB), MRI/ultrasound fusion (FUS-TB), and cognitive fusion (COG-TB). After FUS-TB and COG-TB additional SB was performed. No significant differences in prostate cancer detection and significant prostate cancer were found (MRI-TB 54.5%/32.5%, FUS-TB 49.4%/34.2%, and COG-TB 43.6%/33.3%, p = 0.39/p = 0.98). Combined SBs and TBs versus TBs alone resulted in 1% more csPCa detection (35% vs 34%). There was no significant advantage of one TB technique for the detection of overall prostate cancer, nor for clinically significant prostate cancer. The additional value of SBs was limited.",

keywords = "biopsy, diagnosis, MRI, prostate cancer",

author = "O. Wegelin and L. Exterkate and Barentsz, {J. O.} and {van der Leest}, {M. G.} and Kelder, {J. C.} and Kummer, {J. A.} and W. Vreuls and {de Bruin}, {P. C.} and {de Vocht}, {T. F.} and Nuininga, {J. E.} and Bosch, {J. L.H.R.} and Somford, {D. M.} and {van Melick}, {H. H.E.}",

year = "2019",

month = dec,

day = "1",

doi = "10.1007/s13629-019-0252-9",

language = "Dutch",

volume = "9",

pages = "146--156",

journal = "Tijdschrift voor Urologie",

issn = "2211-3037",

publisher = "Springer Science + Business Media",

number = "8",

}

Wegelin, O, Exterkate, L, Barentsz, JO, van der Leest, MG, Kelder, JC, Kummer, JA, Vreuls, W, de Bruin, PC, de Vocht, TF, Nuininga, JE, Bosch, JLHR, Somford, DM & van Melick, HHE 2019, 'De FUTURE trial; een multicenter RCT naar MRI-geleide prostaatbiopten: Vergelijking van drie technieken van target biopten en vergelijking met systematische biopten', Tijdschrift voor Urologie, vol. 9, no. 8, pp. 146-156. https://doi.org/10.1007/s13629-019-0252-9

TY - JOUR

T1 - De FUTURE trial; een multicenter RCT naar MRI-geleide prostaatbiopten

T2 - Vergelijking van drie technieken van target biopten en vergelijking met systematische biopten

AU - Wegelin, O.

AU - Exterkate, L.

AU - Barentsz, J. O.

AU - van der Leest, M. G.

AU - Kelder, J. C.

AU - Kummer, J. A.

AU - Vreuls, W.

AU - de Bruin, P. C.

AU - de Vocht, T. F.

AU - Nuininga, J. E.

AU - Bosch, J. L.H.R.

AU - Somford, D. M.

AU - van Melick, H. H.E.

PY - 2019/12/1

Y1 - 2019/12/1

N2 - The FUTURE trial is a multicenter RCT on 3 MRI-based target biopsy (TB) techniques among patients with negative systematic biopsies (SBs) and persisting suspicion of prostate cancer. Between 2014 and 2017 665 patients underwent multiparametric MRI. 234 (35%) patients with a PIRADS ≥3 lesion were randomised 1:1:1 for TB: in-bore MRI (MRI-TB), MRI/ultrasound fusion (FUS-TB), and cognitive fusion (COG-TB). After FUS-TB and COG-TB additional SB was performed. No significant differences in prostate cancer detection and significant prostate cancer were found (MRI-TB 54.5%/32.5%, FUS-TB 49.4%/34.2%, and COG-TB 43.6%/33.3%, p = 0.39/p = 0.98). Combined SBs and TBs versus TBs alone resulted in 1% more csPCa detection (35% vs 34%). There was no significant advantage of one TB technique for the detection of overall prostate cancer, nor for clinically significant prostate cancer. The additional value of SBs was limited.

AB - The FUTURE trial is a multicenter RCT on 3 MRI-based target biopsy (TB) techniques among patients with negative systematic biopsies (SBs) and persisting suspicion of prostate cancer. Between 2014 and 2017 665 patients underwent multiparametric MRI. 234 (35%) patients with a PIRADS ≥3 lesion were randomised 1:1:1 for TB: in-bore MRI (MRI-TB), MRI/ultrasound fusion (FUS-TB), and cognitive fusion (COG-TB). After FUS-TB and COG-TB additional SB was performed. No significant differences in prostate cancer detection and significant prostate cancer were found (MRI-TB 54.5%/32.5%, FUS-TB 49.4%/34.2%, and COG-TB 43.6%/33.3%, p = 0.39/p = 0.98). Combined SBs and TBs versus TBs alone resulted in 1% more csPCa detection (35% vs 34%). There was no significant advantage of one TB technique for the detection of overall prostate cancer, nor for clinically significant prostate cancer. The additional value of SBs was limited.

KW - biopsy

KW - diagnosis

KW - MRI

KW - prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=85075574012&partnerID=8YFLogxK

U2 - 10.1007/s13629-019-0252-9

DO - 10.1007/s13629-019-0252-9

M3 - Article

AN - SCOPUS:85075574012

SN - 2211-3037

VL - 9

SP - 146

EP - 156

JO - Tijdschrift voor Urologie

JF - Tijdschrift voor Urologie

IS - 8

ER -

De FUTURE trial; een multicenter RCT naar MRI-geleide prostaatbiopten: Vergelijking van drie technieken van target biopten en vergelijking met systematische biopten

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this